AI tools cut cancer trial time and costs
Bastillepost · 1 SOURCESabout 2 hours ago2 MIN
Summary
A new analysis from the Tufts Center for the Study of Drug Development found that AI agents can reduce cancer drug clinical development timelines by about 10 weeks and lower direct operating costs in later-stage trials by as much as US$5.6 million . The report, first shared with Axios, said AI is moving beyond early drug discovery and is beginning to generate multi-million-dollar value in oncology clinical trials .
Key Points
- Tufts applied Medable's clinical monitoring agent to an undisclosed Phase 2 and Phase 3 oncology drug development programme .
- The analysis found AI tools can speed patient recruitment, result monitoring and data interpretation, removing processes that often take months .
- Tufts executive director Ken Getz said the deployment improved efficiency by reducing site visits, accelerating enrolment and speeding data lock .
- The study estimated efficiency gains increase with the number of tumour indications a drug can target, with net benefit reaching US$565 million for 50 indications .
- Medable executives said AI agents could become standard in some clinical trials within three to five years, including for record-keeping and diversity tracking .
Why It Matters
For Hong Kong readers, the findings point to how AI may help drug developers redirect time and budget toward additional studies rather than repetitive trial administration . The report also underlines that AI cannot solve every bottleneck, because patient matching, consent, drug manufacturing and distribution still require human and operational execution, while AI outputs must also be validated .